{"nctId":"NCT00789724","briefTitle":"Anakinra to Prevent Post-infarction Remodeling","startDateStruct":{"date":"2008-11"},"conditions":["ST Segment Elevation Acute Myocardial Infarction"],"count":10,"armGroups":[{"label":"Anakinra","type":"EXPERIMENTAL","interventionNames":["Drug: Anakinra"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Anakinra","otherNames":["Kineret (TM)"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age \\>18 years\n* Acute (\\<24 hours) onset of chest pain\n* New or presumably new ST elevation on ECG\n* Planned coronary angiography for percutaneous revascularization\n\nExclusion Criteria:\n\n* Inability to give informed consent\n* Late presentation (\\>24 hours)\n* Unsuccessful revascularization or urgent coronary bypass surgery\n* Hemodynamic instability\n* End-stage congestive heart failure (AHA/ACC stage C/D, NYHA class IV)\n* Preexisting severe LV dysfunction (LVEF\\<20%) or severe valvular disease\n* Severe asthma\n* Pregnancy ( pre-enrollment pregnancy test)\n* Contraindications to cardiac MRI or cardiac angiography\n* Severe coagulopathy (INR\\>2.0, Platelet count\\<50,000/mm3)\n* Severe renal insufficiency (creatinine clearance \\<30 ml/min/m2)\n* Recent (\\<14 days) use of anti-inflammatory drugs (NSAIDS excluded)\n* Chronic inflammatory disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Difference Between the Anakinra Arm and Placebo Arm in Change in End-systolic Volume Indices From Baseline to Follow up Exam 10-14 Weeks Later at Cardiac Magnetic Resonance Imaging.","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Difference Between the 2 Arms in the Percentage of Patients With Any of the Following : a) End-systolic or End-diastolic Volume Index Increase >10%; b) Ejection Fraction Decrease >10%; c) E/E'>15 at Follow up","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Difference Between the 2 Arms in Change in the Number of Circulating Endothelial Progenitor Cells From Baseline to Follow up Exam","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Difference Between the 2 Arms in Change in Serum BNP Levels, C-reactive Protein, and Hemoglobin A1c% From Baseline to Follow up","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Difference Between the 2 Arms in the Incidence of Significant Cardiac Arrhythmias in the Acute Phase","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Difference Between the 2 Arms in the Number of Adverse Effects Including a) All Events; b) All Events Requiring Unblinding of the Treatment; c) All Events Requiring Early Termination of the Intervention","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Difference Between the 2 Arms in Change in Oxygen Uptake Kinetics From Baseline to Follow up Exam at Submaximal Cardiopulmonary Exercise Test","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Difference Between the 2 Arms in Change in E/E' Ratios and Myocardial Performance (Tei) Indices From Baseline to Follow up Exam at Transthoracic Echo-color-Doppler Cardiac Exam","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Difference Between the 2 Arms in Change in End-diastolic Volume Indices and Ejection Fraction Values From Baseline to Follow up Exam at Cardiac Magnetic Resonance Imaging","description":null,"paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":5},"commonTop":["Injection site pain"]}}}